Natixis Advisors
ITCI icon

Natixis Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Natixis Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,085
Closed -$2.1M – 1693
2024
Q4 		$2.1M Buy
25,085
+502
+2% +$41.3K ﹤0.01% 1082
2024
Q3 		$1.8M Sell
24,583
-7,077
-22% -$532K ﹤0.01% 1119
2024
Q2 		$2.17M Sell
31,660
-3,592
-10% -$249K ﹤0.01% 1022
2024
Q1 		$2.44M Buy
35,252
+1,364
+4% +$93.7K 0.01% 974
2023
Q4 		$2.43M Buy
33,888
+2,554
+8% +$147K 0.01% 946
2023
Q3 		$1.63M Sell
31,334
-2,510
-7% -$146K 0.01% 1048
2023
Q2 		$2.14M Buy
33,844
+6,385
+23% +$398K 0.01% 941
2023
Q1 		$1.49M Buy
27,459
+11
+0% +$532 0.01% 1029
2022
Q4 		$1.45M Buy
27,448
+6,442
+31% +$323K 0.01% 1033
2022
Q3 		$977K Buy
21,006
+2,099
+11% +$110K ﹤0.01% 1117
2022
Q2 		$1.08M Buy
18,907
+742
+4% +$42.1K ﹤0.01% 1103
2022
Q1 		$1.11M Buy
18,165
+7,558
+71% +$393K ﹤0.01% 1099
2021
Q4 		$555K Buy
+10,607
New +$446K ﹤0.01% 1231
2021
Q1 		– Sell
-10,758
Closed -$342K – 1302
2020
Q4 		$342K Buy
+10,758
New +$283K ﹤0.01% 1166

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HBK Investments
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Davidson Kempner Capital Management
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UBS O'Connor
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Natixis Advisors's ITCI Position: Q1 2025 in Review

Natixis Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 25,085 shares — an estimated $2.1M sold.

Natixis Advisors first reported a position in ITCI in Q4 2020 and held it in 14 quarters. The position peaked at $2.44M in Q1 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Natixis Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Natixis Advisors sold 25,085 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $2.1M.
  • Natixis Advisors first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 14 quarters.
  • Natixis Advisors's Intra-Cellular Therapies Inc. position peaked at $2.44M in Q1 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Natixis Advisors's 13F filing for Q1 2025, filed 8 May 2025.